Loading stock data…
$274.36-6.76 (-2.40%)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
AbbVie Inc. in the Healthcare sector is trading at $274.36 with a market capitalization of $451.5B. Wall Street consensus targets $282.61 (28 analysts), implying a +3.0% move over the next 12 months. The stock is currently near its 52-week high of $283.43, remaining 18.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.99B↑ | $15.00B↓ | $16.62B↑ | $15.78B↑ | $15.42B |
| Gross Profit | $12.70B↑ | $10.78B↓ | $12.07B↑ | $10.47B↓ | $11.08B |
| Operating Income | $6.72B↑ | $4.73B↓ | $5.81B↑ | $4.58B↓ | $5.72B |
| Net Income | $3.61B↑ | $695.00M↓ | $1.82B↑ | $186.00M↓ | $938.00M |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Academic risk and quality models computed from ABBV's own filings and price history, not from analyst opinion.
Strong on 7 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, below the current 25.1% reading.
Fama-French 5-factor market beta. The five factors explain 9% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.